Walter Knirsch1,2, Stefanie Katharina Schuler3,4, Martin Christmann3,4, Roland Weber3,4. 1. Children's Research Center, Zurich, Switzerland. walter.knirsch@kispi.uzh.ch. 2. Pediatric Cardiology, Department of Surgery, Pediatric Heart Center, University Children's Hospital, Steinwiesstrasse 75, CH-8032, Zurich, Switzerland. walter.knirsch@kispi.uzh.ch. 3. Children's Research Center, Zurich, Switzerland. 4. Pediatric Cardiology, Department of Surgery, Pediatric Heart Center, University Children's Hospital, Steinwiesstrasse 75, CH-8032, Zurich, Switzerland.
Abstract
PURPOSE: In 2007, antibiotic prophylaxis (AP) guidelines for infective endocarditis (IE) changed, but the possible influence on the annual incidences of pediatric IE is unclear. METHODS: We studied the clinical and epidemiologic impact of AP change by comparing two time periods before and after change of AP guidelines in a tertiary care center as referral center for a total population of more than 4,500,000 inhabitants. RESULTS: After change of AP guidelines, twenty-five patients were diagnosed for IE at a median age of 6.9 years (range 0.1-19.4, female 48%). Modified Duke criteria were fulfilled for definite (12/25; 48%), or probable IE (13/25; 52%). The frequency of IE (cases per 1000 hospitalized patients) increased from 0.37% (1995-2005) to 0.59% (2006-2017) [p = 0.152], the annual incidence of IE (cases per 1000 CHD patients, < 20 years of age) increased from 0.195 ‰ to 0.399 ‰ [p = 0.072]. Postoperative IE (13/25; 52%), was associated mostly with prosthetic pulmonary valves (12/13; 92%). Pathogens were staphylococci spp. (8/25; 32%), streptococci spp. (7/25; 28%), HACEK (3/25; 12%), other (4/25; 16%), or culture-negative (3/25; 12%). Treatment included antibiotics (25/25; 100%), and cardiac surgery (16/25; 64%). The clinical findings and complications of pediatric IE including mortality (2/25; 8%) did not differ between the two time periods. CONCLUSIONS: Pediatric IE remains a severe cardiac disease with a comparable clinical picture. Unless increasing absolute case numbers of IE, the relative case number of IE remains stable despite AP change. The high number of prosthetic pulmonary valve associated IE needs further evaluation and therapeutic alternatives.
PURPOSE: In 2007, antibiotic prophylaxis (AP) guidelines for infective endocarditis (IE) changed, but the possible influence on the annual incidences of pediatric IE is unclear. METHODS: We studied the clinical and epidemiologic impact of AP change by comparing two time periods before and after change of AP guidelines in a tertiary care center as referral center for a total population of more than 4,500,000 inhabitants. RESULTS: After change of AP guidelines, twenty-five patients were diagnosed for IE at a median age of 6.9 years (range 0.1-19.4, female 48%). Modified Duke criteria were fulfilled for definite (12/25; 48%), or probable IE (13/25; 52%). The frequency of IE (cases per 1000 hospitalized patients) increased from 0.37% (1995-2005) to 0.59% (2006-2017) [p = 0.152], the annual incidence of IE (cases per 1000 CHD patients, < 20 years of age) increased from 0.195 ‰ to 0.399 ‰ [p = 0.072]. Postoperative IE (13/25; 52%), was associated mostly with prosthetic pulmonary valves (12/13; 92%). Pathogens were staphylococci spp. (8/25; 32%), streptococci spp. (7/25; 28%), HACEK (3/25; 12%), other (4/25; 16%), or culture-negative (3/25; 12%). Treatment included antibiotics (25/25; 100%), and cardiac surgery (16/25; 64%). The clinical findings and complications of pediatric IE including mortality (2/25; 8%) did not differ between the two time periods. CONCLUSIONS: Pediatric IE remains a severe cardiac disease with a comparable clinical picture. Unless increasing absolute case numbers of IE, the relative case number of IE remains stable despite AP change. The high number of prosthetic pulmonary valve associated IE needs further evaluation and therapeutic alternatives.
Authors: J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey Journal: Clin Infect Dis Date: 2000-04-03 Impact factor: 9.079
Authors: Denise van der Linde; Elisabeth E M Konings; Maarten A Slager; Maarten Witsenburg; Willem A Helbing; Johanna J M Takkenberg; Jolien W Roos-Hesselink Journal: J Am Coll Cardiol Date: 2011-11-15 Impact factor: 24.094
Authors: Thomas J Cahill; James L Harrison; Paul Jewell; Igho Onakpoya; John B Chambers; Mark Dayer; Peter Lockhart; Nia Roberts; David Shanson; Martin Thornhill; Carl J Heneghan; Bernard D Prendergast Journal: Heart Date: 2017-02-17 Impact factor: 5.994
Authors: Sara K Pasquali; Xia He; Zeinab Mohamad; Brian W McCrindle; Jane W Newburger; Jennifer S Li; Samir S Shah Journal: Am Heart J Date: 2012-05 Impact factor: 4.749
Authors: Mark J Dayer; Simon Jones; Bernard Prendergast; Larry M Baddour; Peter B Lockhart; Martin H Thornhill Journal: Lancet Date: 2014-11-18 Impact factor: 79.321
Authors: Walter Wilson; Kathryn A Taubert; Michael Gewitz; Peter B Lockhart; Larry M Baddour; Matthew Levison; Ann Bolger; Christopher H Cabell; Masato Takahashi; Robert S Baltimore; Jane W Newburger; Brian L Strom; Lloyd Y Tani; Michael Gerber; Robert O Bonow; Thomas Pallasch; Stanford T Shulman; Anne H Rowley; Jane C Burns; Patricia Ferrieri; Timothy Gardner; David Goff; David T Durack Journal: Circulation Date: 2007-04-19 Impact factor: 29.690